PaxVax acquires the FDA-approved typhoid vaccine Vivotif

Privately-held California, USA-based specialty vaccine firm PaxVax says it has acquired the oral typhoid vaccine Vivotif from Crucell Switzerland AG, as well as its manufacturing facility in Thorishaus, near Bern, Switzerland.

Additionally, PaxVax is acquiring marketing, sales and distribution capabilities in select markets including the USA, and certain other assets related to travel vaccines such as hepatitis A. Financial terms of the transaction were not disclosed.

“Typhoid is one of the most commonly delivered travel vaccines, and this strategic transaction establishes PaxVax as an important supplier globally. The manufacturing and sales channel for Vivotif is highly complementary to those for our cholera vaccine candidate, currently finishing Phase III clinical trials, and the site and production assets we are acquiring lay a strong foundation for further growth,” said Kenneth Kelley, chief executive of PaxVax.